RNA interference compositions and screening methods for the identification of novel genes and biological pathways

• US 20050287668A1
• Filed: 10/29/2004
• Published: 12/29/2005
• Est. Priority Date: 11/04/2003
• Status: Abandoned Application

• Current Assignee: Cell Therapeutics, Inc.
• Original Assignee: Cell Therapeutics, Inc.
• Inventors: Finney, Robert E.
• Application Number:
  US10/976,467
• Publication Number:
  US 20050287668A1
• Time in Patent Office: Days
• US Class Current: 435/455
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2320/50 Methods for regulating/modulating their activity

Abstract

The present invention provides compositions and methods for enhancing RNA interference and facilitating the use of long RNA interference molecules. Accordingly, the invention includes a variety of novel applications of RNA interference, including methods related to screening RNA interference molecules using reporter genes to identify biological pathways, genes, therapeutic compounds and biomarkers.

Claims

1. A method of reducing nonspecific suppression of gene expression in response to an introduced double-stranded polynucleotide, comprising:

(a) introducing an agent that attenuates a pathway of nonspecific suppression into a cell; and

(b) introducing an RNAi molecule that induces nonspecific suppression of gene expression into the cell,

wherein said agent reduces nonspecific suppression of gene expression induced by said double-stranded polynucleotide.

2. The method of claim 1, wherein the pathway of nonspecific suppression is the PKR pathway.

3. The method of claim 2, wherein the agent alters the activity of a component of the PKR pathway.

4. The method of claim 3, wherein the agent reduces the activity of PKR.

5. The method of claim 3, wherein the agent increases the activity of elongation initiation factor 2a.

6. The method of claim 1, wherein the pathway of nonspecific suppression is the RNase L pathway.

7. The method of claim 1, wherein the agent is a knockout reagent.

8. The method of claim 7, wherein the knockout reagent is selected from the group consisting of:

targeting vectors and replacement vectors.

9. The method of claim 1, wherein the agent is a knockdown reagent.

10. The method of claim 9, wherein the knockdown reagent is selected from the group consisting of:

antisense RNA;

ribozymes; and

RNAi molecules.

11. The method of claim 10, wherein the RNAi molecule is selected from the group consisting of:

RNA;

RNA hybrids, sense DNA;

antisense RNA hybrids, sense RNA;

antisense DNA hybrids, and DNA;

DNA hybrids.

12. The method of claim 1, wherein the agent is a mutant.

13. The method of claim 1, wherein the agent is a dominant negative.

14. The method of claim 1, wherein the RNAi molecule is at least 30 nucleotides in length.

15. The method of claim 1, wherein the RNAi molecule is at least 50 nucleotides in length.

16. The method of claim 1, wherein the RNAi molecule is at least 100 nucleotides in length.

17. The method of claim 1, wherein the RNAi molecule is at least 200 nucleotides in length.

18. The method of claim 1, wherein the RNAi molecule is at least 500 nucleotides in length.

19. The method of claim 1, wherein the RNAI molecule is at least 1000 nucleotides in length.

20. The method of claim 1, wherein the RNAi molecule comprises a full length cDNA sequence.